sj-pdf-1-avt-10.1177_13596535211062388 ��� Supplemental Material for Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1-infected patients: 336-week rollover study of phase 2b and 3 clinical studies

Supplemental Material, sj-pdf-1-avt-10.1177_13596535211062388 for Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1-infected patients: 336-week rollover study of phase 2b and 3 clinical studies by Jean Michel Molina, Luminita Ene, Pedro Cahn, Gerd F��tkenheuer, Eric Van Wijngaerden, Johan Lombaard, Natalia Zakharova, Veerle Van Eygen, Simon Vanveggel and Rodica Van Solingen-Ristea in Antiviral Therapy